172 related articles for article (PubMed ID: 15852369)
1. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis.
Miller TM; Kaspar BK; Kops GJ; Yamanaka K; Christian LJ; Gage FH; Cleveland DW
Ann Neurol; 2005 May; 57(5):773-6. PubMed ID: 15852369
[TBL] [Abstract][Full Text] [Related]
2. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis.
Miller TM; Kim SH; Yamanaka K; Hester M; Umapathi P; Arnson H; Rizo L; Mendell JR; Gage FH; Cleveland DW; Kaspar BK
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19546-51. PubMed ID: 17164329
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.
Wang LJ; Lu YY; Muramatsu S; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Matsushita T; Hanazono Y; Kume A; Nagatsu T; Ozawa K; Nakano I
J Neurosci; 2002 Aug; 22(16):6920-8. PubMed ID: 12177190
[TBL] [Abstract][Full Text] [Related]
4. AAV6-mediated gene silencing fALS short.
Mandel RJ; Lowenstein PR; Byrne BJ
Mol Ther; 2011 Feb; 19(2):231-3. PubMed ID: 21289637
[No Abstract] [Full Text] [Related]
5. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
Towne C; Aebischer P
Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
[TBL] [Abstract][Full Text] [Related]
6. Amyotrophic lateral sclerosis and gene therapy.
Miller TM; Smith RA; Cleveland DW
Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
[No Abstract] [Full Text] [Related]
7. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
[TBL] [Abstract][Full Text] [Related]
8. RNAi therapy: dominant disease gene gets silenced.
Xu Z; Xia XG
Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
[No Abstract] [Full Text] [Related]
9. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.
Kaspar BK; Lladó J; Sherkat N; Rothstein JD; Gage FH
Science; 2003 Aug; 301(5634):839-42. PubMed ID: 12907804
[TBL] [Abstract][Full Text] [Related]
10. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis.
Wang H; Yang B; Qiu L; Yang C; Kramer J; Su Q; Guo Y; Brown RH; Gao G; Xu Z
Hum Mol Genet; 2014 Feb; 23(3):668-81. PubMed ID: 24108104
[TBL] [Abstract][Full Text] [Related]
11. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.
Towne C; Setola V; Schneider BL; Aebischer P
Mol Ther; 2011 Feb; 19(2):274-83. PubMed ID: 21102563
[TBL] [Abstract][Full Text] [Related]
13. Increase of disease duration of amyotrophic lateral sclerosis in a mouse model by transgenic small interfering RNA.
Yokota T; Sasaguri H; Saito Y; Yamada H; Unno T; Yamamoto Y; Kubodera T; Anzai M; Mitani T; Mizusawa H
Arch Neurol; 2007 Jan; 64(1):145-6. PubMed ID: 17210827
[No Abstract] [Full Text] [Related]
14. Cervical spinal cord delivery of a rabies G protein pseudotyped lentiviral vector in the SOD-1 transgenic mouse. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004.
Tanase K; Teng Q; Krishnaney AA; Liu JK; Garrity-Moses ME; Boulis NM
J Neurosurg Spine; 2004 Jul; 1(1):128-36. PubMed ID: 15291033
[TBL] [Abstract][Full Text] [Related]
15. Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model.
Saito Y; Yokota T; Mitani T; Ito K; Anzai M; Miyagishi M; Taira K; Mizusawa H
J Biol Chem; 2005 Dec; 280(52):42826-30. PubMed ID: 16221675
[TBL] [Abstract][Full Text] [Related]
16. Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice.
Ayers JI; Fromholt S; Sinyavskaya O; Siemienski Z; Rosario AM; Li A; Crosby KW; Cruz PE; DiNunno NM; Janus C; Ceballos-Diaz C; Borchelt DR; Golde TE; Chakrabarty P; Levites Y
Mol Ther; 2015 Jan; 23(1):53-62. PubMed ID: 25228069
[TBL] [Abstract][Full Text] [Related]
17. [Gene therapy of ALS with RNA interference].
Yokota T
Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
[TBL] [Abstract][Full Text] [Related]
18. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
[TBL] [Abstract][Full Text] [Related]
19. Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice.
Locatelli F; Corti S; Papadimitriou D; Fortunato F; Del Bo R; Donadoni C; Nizzardo M; Nardini M; Salani S; Ghezzi S; Strazzer S; Bresolin N; Comi GP
Ann Neurol; 2007 Jul; 62(1):81-92. PubMed ID: 17503505
[TBL] [Abstract][Full Text] [Related]
20. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis.
Kaspar BK; Frost LM; Christian L; Umapathi P; Gage FH
Ann Neurol; 2005 May; 57(5):649-55. PubMed ID: 15852403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
